ZOMETA LYOPHILIZED POWDER POWDER FOR SOLUTION

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Dostupné s:

NOVARTIS PHARMACEUTICALS CANADA INC

ATC kód:

M05BA08

INN (Mezinárodní Name):

ZOLEDRONIC ACID

Dávkování:

4MG

Léková forma:

POWDER FOR SOLUTION

Složení:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG

Podání:

INTRAVENOUS

Jednotky v balení:

6ML

Druh předpisu:

Prescription

Terapeutické oblasti:

BONE RESORPTION INHIBITORS

Přehled produktů:

Active ingredient group (AIG) number: 0141761001; AHFS:

Stav Autorizace:

CANCELLED POST MARKET

Datum autorizace:

2008-10-31

Charakteristika produktu

_ _
_Page 1 of _47
PRODUCT MONOGRAPH
Pr
ZOMETA* Lyophilized Powder
(Zoledronic acid for Injection)
4 mg/vial
Pr
ZOMETA* Concentrate
(Zoledronic acid for Injection)
4 mg zoledronic acid/5 mL incorporated as the monohydrate
Bone Metabolism Regulator
Novartis Pharmaceuticals Canada Inc.
Dorval, Quebec
H9S 1A9
Date of Preparation:
August 16, 2000
Date of Revision:
September 20, 2005
CONTROL # 097402
Pr
ZOMETA* is a registered trademark
_ _
_Page 2 of _47
Table of Contents
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................9
DRUG INTERACTIONS
....................................................................................................5
DOSAGE AND
ADMINISTRATION..............................................................................17
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND
STABILITY..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................27
PHARMACEUTICAL
INFORMATION..........................................................................27
CLINICAL
TRIALS.......................................